For biotech companies, the decision to partner or launch on your own will define your long-term success. Historically, the decision to sell to a larger company for launch was the best strategy. Today, more biotech companies than ever are successfully launching on their own. What’s behind this trend and what’s driving their success?
In this webinar, Michael Kleinrock, of The IQVIA Institute for Human Data Science, will moderate a panel of launch and market access experts as they discuss how biotech companies have resolved some of their key challenges to enable launch success. Specific points of the discussion will include:
After this discussion, you should walk away knowing:
Sarah Rickwood has 26 years’ experience as a consultant to the pharmaceutical industry, having worked in Accenture’s pharmaceutical strategy practice prior to joining IQVIA. She has an extremely wide experience of international pharmaceutical industry issues, having worked most of the world’s leading pharmaceutical companies on issues in the US, Europe, Japan, and leading emerging markets.
David Wolter brings more than 15 years of management consulting experience to his position as Vice President at IQVIA. He leads the US Strategy and Portfolio Analysis team, assisting clients with a wide range of solutions including product valuation, analog analyses, user-friendly valuation models, and decision-analysis training.
Adam Sohn, Vice President, Global Consulting at IQVIA, is responsible for developing and executing global product offerings. During his 22+ year healthcare career, Adam has specialized in commercial strategy and global policy development for the life sciences industry. Adam supports both small and large biopharmaceutical companies with improving access, funding, and commercialization of niche and blockbuster drugs.